Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Number of Topics Discussed by PAFSC Second Committee Exceeds that of First Committee for 1st Time in 10 Years: Jiho Tally
April 28, 2015
- Patient-Initiated Mixed Care Used Only When Compassionate Access Can’t Be Applied: Minister
April 28, 2015
- PAFSC Second Committee Backs Approval of Add’l Indication for PegIntron
April 27, 2015
- AMED, JPMA Discussing Joint Use of Compounds, with Policy Announcement Expected in Early June: Dr Suematsu of AMED
April 27, 2015
- MHLW Looking into Drug Maker Payments to PAFSC Members: Shiozaki
April 24, 2015
- LDP Weighs Clinical Development Infrastructure Utilizing Patient Registry
April 24, 2015
- Council on Unapproved Drugs to Issue Development Requests Immediately In Cases of Unanimous Approval by Working Groups
April 24, 2015
- MHLW Orders Revision of Package Inserts for Plavix
April 24, 2015
- Polyethylene Glycol Has Great Unmet Medical Need: Panel
April 23, 2015
- MHLW Official Jo Hints at Possible Move-Up of Generic Roadmap
April 23, 2015
- Find Solid Candidates from Early Development Stage: MHLW’s Mori
April 23, 2015
- Ease Post-Marketing Burdens for Intractable Disease Treatments: JPMA Exec
April 22, 2015
- AMED Chief Envisages Tapping Private Funds to Fuel R&D
April 22, 2015
- Editor’s Pick: Five Healthcare News Headlines for April 6 - 19
April 20, 2015
- Govt Checks on Progress of Healthcare R&D Promotion Plan
April 20, 2015
- Govt Panel Members Call for Medication Control to Eliminate Unused Drugs
April 17, 2015
- Govt Panel to Prod Chuikyo to Revisit 14-Day Prescription Limit
April 17, 2015
- Who Will Foot the Bill for Cost-Effective Assessments?: Chuikyo Chair
April 16, 2015
- Japan Faces Imperative to Increase Biostatisticians to Boost Clinical Research Quality
April 16, 2015
- PAFSC 1st Committee to Discuss Add’l Indication for Cymbalta on April 28
April 15, 2015
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…